Collectively, we show that CALR variants are genuine ERAD substrates and propose that modulations of ERAD activity could represent a therapeutic target for CALR-mutated MPN patients to attenuate CALR variant-dependent MPL activation. The gene discussed is CALR; the disease is myeloproliferative disorder.